Amarin Corp plc (ADR)

  • Acquisitions Can’t Save Falling Revenues and Dividend Yield

    By Mohsin Saeed - August 19, 2013 | Tickers: AMRN, AZN, OMTH

    AstraZeneca (NYSE: AZN) has been badly hit by the patent cliff. Its key franchises, Crestor and Seroquel, are facing generic threat after losing patent protection in multiple countries. There has been a sharp decline in sales, and management seems unable to stem the flow.

    The company has made some smart acquisitions, but none of the assets will pay off before the end of 2016. It has recently acquired Omthera (NASDAQ: OMTHmore »)

  • Does New Data Make This Biotech a Good Buy?

    By Sherrie Stone - August 15, 2013 | Tickers: AMRN, MNKD

    Apparently, the third time's a charm for MannKind’s (NASDAQ: MNKD) Afrezza, an inhaled insulin device that has been rejected by the FDA on two other occasions. MannKind accepted guidance from the FDA, recently completed two Phase 3 trials for Type 1 and 2 diabetes, and now will likely earn a marketing approval. On Wednesday, the stock traded higher by nearly 11% after this news, making its gains 230 more »

  • An Under-the-Radar Drug Launch That's Producing Massive Gains

    By Brian Nichols - August 13, 2013 | Tickers: AMRN, ARIA, SNTS

    Ariad Pharmaceuticals’ (NASDAQ: ARIA) Iclusig and Amarin Corporation’s (NASDAQ: AMRN) Vascepa may have been two of the most hyped drugs of the last few years, but Uceris from Santarus (NASDAQ: SNTS) has stolen the spotlight. This is a drug that is beating all sales expectations, and leading some to wonder if Santarus’ impressive stock rally can continue.

    Three Drugs With Different Outlooks

    The reason that these three companies, and more »

  • Can Acquisitions Save The Declining Revenues?

    By Mohsin Saeed - August 6, 2013 | Tickers: AMRN, AZN, OMTH

    AstraZeneca (NYSE: AZN) is one of the worst affected companies by the patent cliff. It key franchises, Crestor and Seroquel, are facing generic threat after losing patent protection in multiple countries. Despite the best efforts of its new management, the revenues continue to decline.

    The company has made some good acquisitions, but none of the assets will pay off before the end of 2016. It has recently acquired Omthera (NASDAQ: OMTHmore »)

  • Why You Shouldn’t Bet On This Product Launch Yet

    By Sherrie Stone - July 10, 2013 | Tickers: AMRN, DNDN

    For the last few weeks, there has been a heated debate regarding the success or lack thereof from biotechnology company Amarin's (NASDAQ: AMRN) new product launch. Those who are bullish note encouraging month-over-month script growth in the thousands for the cardiovascular drug Vascepa. However, as the company issues even more shares to fund Vascepa's marketing, is it still worth an investment?

    Month

    Scripts Written

    Month-Over-Month % Gain

    February

    3 more »

  • Should You Buy the Hype Surrounding This Product Launch?

    By Sherrie Stone - July 1, 2013 | Tickers: AMRN, ARIA, GALE, VVUS

    While the analysis of peak sales and potential patient populations may be appealing to most, it costs a great deal of money to launch a new product with success. In the case of Galena Biopharma (NASDAQ: GALE), the company doesn’t have the cash, but touts tremendous sales potential, so might the company succeed anyway?

    The reality of launching drugs in healthcare

    I would like to share with you something more »

  • A Winning Biotechnology Bet

    By Mohsin Saeed - June 10, 2013 | Tickers: AMRN, AZN, OMTH

    Amarin (NASDAQ: AMRN) has recently launched its primary product candidate Vascepa into the market. The drug is an omega-3 fatty acid eicosapentaenoic which has been approved by the FDA for treatment of high levels of TGT. 

    A market launch of Vascepa was never part of the plan, investors expected Amarin to cut a multi-billion acquisition deal instead, so everyone could go back home with pockets full of cash.

    However, the more »

  • AstraZeneca’s Acquisition of Omthera Pharma Is a Desperate Act

    By Nicholas Kitonyi - June 8, 2013 | Tickers: AMRN, AZN, GSK, OMTH, PFE

    AstraZeneca (NYSE: AZN) announced the acquisition of Omthera Pharmaceuticals (NASDAQ: OMTH), a company that went public just last month (April 11). Omthera listed a price of $8 per share, and has since struggled to breach that mark until AstraZeneca came up with an offer to acquire the company. Omthera is a specialty drug maker with a keen focus on patients who have high levels of fats, called triglycerides, in their more »

  • Which of These Billion-Dollar Biotechs Is a Buy?

    By Brian Nichols - June 1, 2013 | Tickers: AMRN, LXRX

    Regardless of Anchor, Things Are Looking Up!

    It has been a rough year for Amarin (NASDAQ: AMRN) and its long-term investors. The stock has lost more than 40% of its value over the last year following the approval and launch of its drug Vascepa.

    Prior to Vascepa’s FDA approval it was touted as a blockbuster drug in the treatment of high triglycerides. However, after a slower-than-expected launch; no buyout more »

  • Two Different Outlooks for Two Tuesday Performers

    By Brian Nichols - May 2, 2013 | Tickers: AMRN, RPTP

    It’s nothing new for biotech stocks to see significant movement in a day’s session, although sometimes these moves create a trap for the retail investors who buy at inflated prices. Hence I am looking at two stocks in particular that saw nice jumps on Tuesday but have different outlooks.

    Stock Gains with FDA Approval

    Raptor Pharmaceuticals (NASDAQ: RPTP) saw a gain of 8.70% on Tuesday after announcing more »

  • Can This New Drug Win Against Established Competitors?

    By Shas Dey - April 27, 2013 | Tickers: ABT, AMRN, GSK

    It’s not just about offering a better drug, but it’s also about launching it at the right time in the market. This is what I learned while studying about Amarin (NASDAQ: AMRN), which has a new drug out to cater to a vast number of patients in the cardiovascular realm. The phase III trial results have all been positive, yet, the presence of established competitors can leave some more »

  • Adage Capital Management Owns 5.4% of This Biotech Stock

    By Meena Krishnamsetty - April 10, 2013 | Tickers: ABT, AMRN, BIIB, DNDN, MDVN

    According to a 13G filed with the SEC, Adage Capital Management, a large hedge fund managed by Phil Gross and Robert Atchinson, owns just over 4 million shares of Medivation (NASDAQ: MDVN), a $3.6 billion market cap biotechnology company. Our database of 13F filings shows Adage with a position of 2.1 million shares as of the beginning of January, so in the last three months the fund has more »

  • Adage Capital Management Owns 5.4% of This Biotech Stock

    By Meena Krishnamsetty - April 8, 2013 | Tickers: ABT, AMRN, BIIB, DNDN, MDVN

    According to a 13G filed with the SEC, Adage Capital Management, a large hedge fund managed by Phil Gross and Robert Atchinson, owns just over 4 million shares of Medivation (NASDAQ: MDVN), a $3.6 billion market cap biotechnology company. Our database of 13F filings shows Adage with a position of 2.1 million shares as of the beginning of January, so in the last three months the fund has more »

  • AstraZeneca is Headed in the Right Direction

    By Mohsin Saeed - March 27, 2013 | Tickers: AMRN, AZN, SHPG

    In my last report on AstraZeneca (NYSE: AZN), I focused on the patent expiry of Seroquel IR and the resultant decline in company sales. According to recent news, the troubles of AstraZeneca are still not over and the company is cutting approximately 2,300 sales and admin jobs. This is part of a large plan put forward by the new CEO to jump start falling sales.

    Strategy shift

    The new more »

  • More Good News for Amarin

    By Mohsin Saeed - March 14, 2013 | Tickers: AMRN, GSK

    Last year, a number of drugs received FDA approval. The drug authority has rolled out one approval after another, maybe to compensate for the patent cliff most large pharmaceuticals are facing. These approvals have a significant impact on single drug companies, such as Amarin (NASDAQ: AMRN). The company's stock has traded as high as $19.50 on positive expectations from its star drug Vascepa. Small biopharmaceuticals with approved candidates more »

  • 3 Bio-Pharmaceuticals You Can't Ignore

    By Mohsin Saeed - February 26, 2013 | Tickers: AMRN, ARNA, VVUS

    The last year has been a stellar one for the biotechnology industry. The industry has easily outperformed the market, with all of its indices, including the Amex Biotechnology Index ETF (FBT), the SPDR S&P Biotech ETF (XBI) and iShares NASDAQ Biotechnology Index (IBB), giving returns of more than 20%. The entire industry is heavily dependent for growth on the approvals of the Food and Drug Administration (FDA). According to more »

  • A Buyout In Amarin Is Imminent!

    By Terry Chrisomalis - February 22, 2013 | Tickers: AMRN, GSK, PFE

    All throughout Wall Street we keep hearing about Amarin (NASDAQ: AMRN) being bought out by some type of Big Pharma company in the future.  It's all rumors circling around, but it's one of the most talked about biotech topics on other popular stock trading websites. Amarin, though, in my opinion will be bought out eventually, because the market that the company targets is huge. That market is people more »

  • Reasons to Buy This Pharmaceutical Company

    By Mohsin Saeed - February 11, 2013 | Tickers: AMRN, GSK, NEPT

    The small pharmaceutical companies have a number of weaknesses when compared to big pharmaceuticals. While they usually have competent management that can effectively oversee the development of a drug candidate, it is extremely rare that they also possess the resources to effectively market their own product. This is the very reason small pharmaceuticals are such attractive acquisition plays. If a company has managed to develop an interesting candidate it is more »

  • What Exactly is Wrong With Amarin Shares

    By Chris Lau - January 24, 2013 | Tickers: AMRN, ARNA, VVUS

    Since peaking in July, 2012 at around $15, shares of Amarin (NASDAQ: AMRN) declined steadily to close recently at $8.47. Amarin was flying high last summer because investors were betting that the company would be taken over. Investors also expected that positive FDA decisions would drive Amarin shares higher. More recently, in comparison to other pharmaceutical companies rallying on FDA-related news, Amarin continued an additional decline of over 20 more »

  • Four Sell-Offs that Might Create Opportunity

    By Brian Nichols - January 22, 2013 | Tickers: AMRN, ARNA, INTC, MLNX

    Last Friday there were numerous high-profile stocks to fall lower -- some caught my attention while others did not. The ones that did catch my attention were violent falls, or aggressive selling, due to fundamental and technical fear. However, in the midst of these downtrends there could be value, and I am looking at four such situations.

    Bad News for Intel Might be Priced Into the Stock

    Intel (NASDAQ: INTC) has more »

  • Page 1 of 2